- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03049865
Gait Speed at Discharge as a Marker for Readmission (GASP)
February 9, 2017 updated by: Martin Holzmann, Karolinska University Hospital
Gait Speed at Discharge as a Marker for Readmission - The GASP Study
The principal aim is to assess if a simple test, the time it takes to walk 10 meters for a patient about to be discharged after a hospital stay for an acute illness, is related to the risk of readmission.
Study Overview
Status
Not yet recruiting
Study Type
Observational
Enrollment (Anticipated)
1000
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
51 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All patients who are admitted to hospital from the emergency department are eligible for inclusion.
Description
Inclusion Criteria:
- >50 years of age Patient discharged to home, or temporary short stay nursing home Expected survival >90 days The ability to read or understand the instructions and to give informed consent.
Exclusion Criteria:
- Planned hospital stay, i.e. the patient was admitted electively The including investigator is directly involved in the care of the patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Readmission
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Readmissions
Time Frame: 90,180, 365 days
|
90,180, 365 days
|
|
All-cause mortality
Time Frame: 6, 12, 24, 36, 60 months
|
6, 12, 24, 36, 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 9, 2017
Primary Completion (Anticipated)
December 31, 2017
Study Completion (Anticipated)
December 31, 2027
Study Registration Dates
First Submitted
February 8, 2017
First Submitted That Met QC Criteria
February 9, 2017
First Posted (Actual)
February 10, 2017
Study Record Updates
Last Update Posted (Actual)
February 10, 2017
Last Update Submitted That Met QC Criteria
February 9, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- Dnr 2016/2174-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.